ОбзорГрафикПрофильОсновная статистикаФинансовые показателиТехническийНовости
Деривативы
TraderScreen

BASILEA N/  CH0011432447  /

SIX Swiss Exchange
24.12.2024  22:10:00 Изменение 0.000 Объем сделки Бид23.12.2024 Предложение23.12.2024 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
41.150CHF 0.00% -
Оборот: -		 41.000Величина цены спроса: 200 41.200Величина цены предложения: 200 539.06 млнCHF - 47.30
GlobeNewswire 27.08 European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) an...
GlobeNewswire 21.08 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 13.08 Basilea reports strong 2024 half-year results and significantly increases full-year revenue and prof...
GlobeNewswire 09.07 ImCheck Appoints Stephan Braun as Chief Medical Officer
GlobeNewswire 20.06 Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
GlobeNewswire 16.05 Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire 03.05 Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire 24.04 Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire 09.04 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire 04.04 Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire 11.03 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire 13.02 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire 19.01 Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire 15.01 Basilea announces acquisition of preclinical antibiotics program from Spexis
GlobeNewswire 05.01 Basilea provides portfolio status update
GlobeNewswire 11.12.2023 Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire 20.11.2023 Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers thir...
GlobeNewswire 13.11.2023 Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
GlobeNewswire 31.10.2023 Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage...
GlobeNewswire 19.10.2023 Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold i...
GlobeNewswire 17.10.2023 Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
GlobeNewswire 02.10.2023 Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
GlobeNewswire 28.09.2023 Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for th...
GlobeNewswire 15.08.2023 Basilea reports strong revenue and profit growth in first half-year 2023
GlobeNewswire 08.03.2022 Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at...